Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation

2020 ◽  
Vol 60 (6) ◽  
pp. 768-774 ◽  
Author(s):  
Xiao‐Chen Wei ◽  
Ming‐Feng Zhao ◽  
Xin Li ◽  
Xia Xiao
Keyword(s):  
Staphylococcus Aureus ◽  
Monte Carlo Simulation ◽  
Monte Carlo ◽  
Enterococcus Faecium ◽  
Pediatric Patients ◽  
Pharmacodynamic Analysis

scholarly journals 1507. Pharmacodynamic Target Attainment of Daptomycin Against Staphylococcus aureus for Treatment of Pediatric Osteomyelitis

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S548-S549
Author(s):  
Grant Stimes ◽  
Jennifer E Girotto ◽  
Joshua D Courter
Keyword(s):  
Staphylococcus Aureus ◽  
Monte Carlo Simulation ◽  
Monte Carlo ◽  
Pediatric Patients ◽  
Age Groups ◽  
Pharmacokinetic Studies ◽  
Pharmacokinetic Models ◽  
Limited Data ◽  
Target Attainment ◽  
Starting Point

Abstract Background Daptomycin (DAP) is lipopeptide that frequently is used to treat infections caused by Staphylococcus aureus in adult patients. There are limited data using daptomycin in pediatric patients for the treatment of osteomyelitis caused by S. aureus. This study’s objective is to describe pharmacodynamic (PD) target attainment of daptomycin in pediatric patients with osteomyelitis. Methods Medline was queried to obtain PD targets, pediatric pharmacokinetic models, and bone penetration information to build a model for DAP. A 10,000 subject Monte Carlo simulation was performed to estimate steady-state concentrations in the bone. Simulations modeled 30-minute infusions with using 12 mg/kg/dose IV q24h for patients less than 7 years and 10 mg/kg/dose IV q24h for patients 7 years and older. Goal PD targets were: AUC24: MIC of 666 μg hours/mL for log1 killing and AUC24: MIC of 1,061 for log2 killing. The CLSI breakpoint of 1 mg/L was used as a starting point and MIC’s were analyzed below that level. Results PD target attainment in percentages is listed for DAP below in Tables 1 and 2 and are separated by age groups of patients. Conclusion The studied DAP doses did not reach any PD target attainment at the CLSI breakpoint of 1 mg/L. Based on these data, DAP should not be empirically used to treat SA osteomyelitis unless the exact MIC is known. Furthermore, modern pediatric pharmacokinetic studies of DAP for pediatric osteomyelitis are warranted. Disclosures All authors: No reported disclosures.

scholarly journals Time-kill curves of daptomycin and Monte Carlo simulation for the treatment of bacteraemia caused by Enterococcus faecium

2019 ◽  
Vol 51 (1) ◽  
pp. 169-176 ◽  
Author(s):  
Bruna Kochhann Menezes ◽  
Izabel Almeida Alves ◽  
Keli Jaqueline Staudt ◽  
Betina Montanari Beltrame ◽  
Letícia Venz ◽  
...  
Keyword(s):  
Monte Carlo Simulation ◽  
Monte Carlo ◽  
Enterococcus Faecium ◽  
Time Kill
Sign in / Sign up

Export Citation Format

Share Document